Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

TRAF4 overexpression is a common characteristic of human carcinomas

Oncogene volume 26, pages 142–147 (2007)Cite this article

Abstract

Tumor necrosis factor receptor (TNFR) associated factor 4 (TRAF4) was initially identified as a gene amplified and overexpressed in breast carcinomas. Our aim was to evaluate whether TRAF4 protein overexpression exists in other cancer types. Immunohistochemistry analysis of tumor samples from 623 patients with 20 different tumor types showed that TRAF4 was overexpressed in 268 tumors (43%), including 82 of 137 lung adenocarcinomas (60%). Interestingly, 32 primary tumors and their matching metastases exhibited mostly similar TRAF4 expression pattern. TRAF4 protein overexpression was limited to cancer cells and the subcellular localization was consistently cytoplasmic in a large majority of cases. To investigate changes in TRAF4 gene copy number, 125 cases from six different types of carcinomas were also analysed by fluorescence in situ hybridization. Out of the 28 cases (22%) showing an increased TRAF4 gene copy number, 23 (82%) were overexpressing the protein. Thus, TRAF4 gene amplification is one of the mechanisms responsible for TRAF4 protein overexpression in human cancers. Considering that TRAF4 is located at 17q11.2 in a region of amplification devoid of known oncogenes and is commonly overexpressed in cancer, our data support an oncogenic role for TRAF4.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abell AN, Johnson GL . (2005). J Biol Chem 280: 35793–35796.

  • Aggarwal BB . (2003). Nat Rev Immunol 3: 745–756.

  • Balsara BR, Testa JR . (2002). Oncogene 21: 6877–6883.

  • Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R . (1996). Cancer Res 56: 3886–3890.

  • Bowers AJ, Boylan JF . (2004). Gene 328: 135–142.

  • Chung JY, Park YC, Ye H, Wu H . (2002). J Cell Sci 115: 679–688.

  • Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI et al. (1998). Proc Natl Acad Sci USA 95: 8703–8708.

  • Esparza EM, Arch RH . (2004). Cell Mol Life Sci 61: 3087–3092.

  • Glauner H, Siegmund D, Motejadded H, Scheurich P, Henkler F, Janssen O et al. (2002). Eur J Biochem 269: 4819–4829.

  • Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B et al. (2002). Br J Cancer 86: 1449–1456.

  • Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E et al. (2002). Cancer Res 62: 6240–6245.

  • Kauraniemi P, Barlund M, Monni O, Kallioniemi A . (2001). Cancer Res 61: 8235–8240.

  • Krajewska M, Krajewski S, Zapata JM, Van Arsdale T, Gascoyne RD, Berern K et al. (1998). Am J Pathol 152: 1549–1561.

  • Li JM, Fan LM, Christie MR, Shah AM . (2005). Mol Cell Biol 25: 2320–2330.

  • Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L et al. (2004). Cancer Res 64: 6453–6460.

  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Nature 406: 747–752.

  • Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE et al. (2002). Proc Natl Acad Sci USA 99: 12963–12968.

  • Regnier CH, Masson R, Kedinger V, Textoris J, Stoll I, Chenard MP et al. (2002). Proc Natl Acad Sci USA 99: 5585–5590.

  • Regnier CH, Tomasetto C, Moog-Lutz C, Chenard MP, Wendling C, Basset P et al. (1995). J Biol Chem 270: 25715–25721.

  • Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). Proc Natl Acad Sci USA 101: 9309–9314.

  • Sax JK, El-Deiry WS . (2003). J Biol Chem 278: 36435–36444.

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Science 244: 707–712.

  • Takeshita F, Ishii KJ, Kobiyama K, Kojima Y, Coban C, Sasaki S et al. (2005). Eur J Immunol 35: 2477–2485.

  • Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R et al. (1995). Genomics 28: 367–376.

  • Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ . (2003). Proc Natl Acad Sci USA 100: 15901–15905.

  • Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M et al. (2004). Neoplasia 6: 240–247.

  • Wu RF, Xu YC, Ma Z, Nwariaku FE, Sarosi Jr GA, Terada LS . (2005). J Cell Biol 171: 893–904.

  • Xu YC, Wu RF, Gu Y, Yang YS, Yang MC, Nwariaku FE et al. (2002). J Biol Chem 277: 28051–28057.

  • Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H et al. (1999). J Biol Chem 274: 30202–30208.

Download references

Acknowledgements

We thank DJ Heard for critical reading of the manuscript, C Tomasetto for helpful discussions, F Devez and V Ducruit for expert technical assistance. The BAC clone RP11-386F9 was kindly provided by M Rocchi. This work was supported by funds from the Institut National de la Santé et de la Recherche Médicale, the Association pour la Recherche sur le Cancer (CH Régnier, contract no. 4801) and the Alliance des Recherches sur le Cancer.

Author information

Authors and Affiliations

  1. Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 255 d'Immunologie Cellulaire et Clinique, Université Pierre et Marie Curie Paris VI, Université Paris-Descartes, Faculté de Médecine, Centre de Recherches Biomédicales des Cordeliers, Paris, France

    S Camilleri-Broët, I Cremer, W-H Fridman, C Sautès-Fridman & C H Régnier

  2. Université Paris-Descartes, Faculté de Médecine, AP-HP Hôtel-Dieu, Paris, France

    S Camilleri-Broët, B Marmey, F Viguié & J Audouin

  3. Université Pierre et Marie Curie Paris VI, Faculté de Médecine, AP-HP La Pitié-Salpêtrière, Paris, France

    E Comperat

  4. Département de Pathologie Moléculaire, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UPR 6520 CNRS, INSERM U596, Université Louis Pasteur, Illkirch, France

    M-C Rio

Authors
  1. S Camilleri-Broët
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Marmey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Comperat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Viguié
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Audouin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-C Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W-H Fridman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Sautès-Fridman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C H Régnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C H Régnier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camilleri-Broët, S., Cremer, I., Marmey, B. et al. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26, 142–147 (2007). https://doi.org/10.1038/sj.onc.1209762

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209762

Keywords

This article is cited by

Search

Advanced search

Quick links